Sonova Holding AG earnings date
Want to see CH:SOON full AI Analyst Report?
Sonova Holding AG (SOON) Q2 2027 Earnings Report
CH:SOON Q2 2027 EPS Results
- Actual EPS
- CHF 5.18
- Consensus EPS
- CHF 4.44
- Beat/Miss
- Beat by +CHF 0.74
- One Year Ago EPS
- CHF 3.56
CH:SOON Q2 2027 Revenue Results
- Actual Revenue
- ―
- Expected Revenue
- CHF 1.82B
- Beat/Miss
- ―
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q2 2027
- Date
- 11/12/2026
- Time
- Before Open
- Conference Call
- Thursday, November 12, 2026
Sonova Holding AG's next earnings date is estimated for May 18, 2027, based on past reporting schedules.
Q2 2027 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2027 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2027 Earnings Call Summary
The call was strongly positive overall. Sonova reported broad-based sales growth, significant core EBIT and EPS expansion, higher cash generation and continued market share gains, while raising full-year sales and EBIT guidance. The main challenges were the 10% decline in cochlear implant sales, uncertainty around U.S. regulatory approval for Integro, lower reported EPS from discontinued operations, retail marketing efficiency and expected second-half normalization and customer-related headwinds.
Sonova raised its full year market growth assumptions to 3% to 5% from 2% to 4% previously, expects consolidated sales growth of 6% to 8% compared with 5% to 8% previously, and raised core EBIT growth guidance to 10% to 13% compared with 7% to 10% previously; it expects strategic investments in the second half by low double-digit CHF million amount, supports a 5% to 10% midterm sales growth target, expects currency translation to be broadly neutral for sales and core EBIT for the full year based on exchange rates as of early November, expects Integro to support an improvement in the second half in cochlear implants, the extent of which is subject to the timing of regulatory approval in the United States, remains within its expected CHF 35 million to CHF 40 million for noncore costs for the full year, and remains on track to invest around CHF 80 million to CHF 100 million annually in bolt-on acquisitions while remaining within its net debt-to-EBITDA corridor of 1x to 1.5x.
- Strong First-Half Group GrowthGroup sales reached CHF 1.8 billion, increasing 7.5% in local currencies and 6.7% in Swiss francs. Organic growth contributed 7 percentage points, M&A contributed 0.5 percentage points, and foreign exchange reduced reported growth by 0.8 percentage points.
- Hearing Instruments Delivered Higher Growth and MarginsHearing instrument sales grew 9%, core EBIT increased 26%, and the core EBIT margin expanded by 260 basis points to 22%.
- Wholesale Market Share Gains ContinuedWholesale grew 11%, marking 12 months of double-digit growth and 11 consecutive quarters of market share gains. Share in tracked markets increased from the mid-20s to the low 30s percent. Growth was supported by expanded major customer relationships, increased VA deliveries, Virto R, Infinio Ultra and the EON launch.
- EON Launch Received Strong Early ResponseEON, featuring real-time AI in a smaller device with improved acoustics, connectivity and wind performance, made a healthy contribution despite launching only in the final weeks of the period. On-time fulfillment was above 95%, compared with 64% for the earlier Infinio launch, and early retail and wholesale complaints were down by more than 1/3. Among U.S. audiologists, Phonak ranked #1 for the attractiveness of recent product launches.
- Strong Sphere Mix and Rechargeable Portfolio PerformanceAround 2/3 of devices sold globally in the first 2 months were Sphere, with management expecting the mix to normalize over time but remain above Infinio Ultra. The IT rechargeable portfolio, including Virto R under Phonak and Insera under Unitron, continued to perform strongly, and share remained broadly stable despite competitor launches.
- Virto R Established a Leading PositionVirto R was described as an incredible success in the IT rechargeable category. Within months, Sonova was above 60% share in the VA, realized sales were higher than the previously indicated CHF 120 million, and Virto R remained #1 after new competition entered the category.
- Retail Growth and Expansion ContinuedRetail sales grew around 7% in the first half, with more than 5% organic growth and acceleration in the last quarter. M&A activity was picking up, including Høreservice Danmark and Harbor Audiology. Høreservice Danmark strengthens Sonova's position in a mobile solution channel that is growing faster than the average market.
- Broad-Based Regional GrowthEMEA and Latin America grew 6.8%, North America grew 7.5%, and Asia Pacific led with 11.4% growth. Asia Pacific hearing instrument growth was in the mid-teens, led by Australia, China and Japan. Japan grew double digits at more than 20%, China wholesale grew in the double-digit mid-teens, and India also grew, with management describing the regional growth as profitable.
- Sonova Outgrew a Stronger Hearing Aid MarketBased on tracked market data and company estimates, the global hearing aid market grew around 5% in the first half, with acceleration in the second quarter. Sonova grew substantially faster than the market and continued to gain market share.
- Gross Margin and Operating Leverage ImprovedCore gross profit increased to CHF 1.4 billion and core gross margin reached 74.7%, an improvement of around 230 basis points in local currency. The improvement was driven by strong volume growth, positive average selling price in wholesale and retail, and the absence of temporary manufacturing and logistics costs incurred in the prior-year period. Core operating expenses grew 6.9%, slightly below sales.
- Core EBIT and EPS Growth Were StrongCore EBIT increased 22.9% to CHF 384 million, and the core EBIT margin rose to 20.9% from 18.4%, representing 260 basis points of expansion. Core EPS increased 38% to CHF 5.37, while reported EPS from continuing operations was CHF 5.18.
- Cash Generation and Returns ImprovedOperating cash flow increased to CHF 378 million. Operating free cash flow rose to CHF 287 million from CHF 90 million, and free cash flow increased to CHF 266 million from CHF 60 million in the prior-year period. ROCE improved to 20.9% from 19.5%, while net debt-to-EBITDA was 1.1x.
- Operational Transformation Remains on TrackSonova committed CHF 50 million of investment in its operational transformation program and remains on track to deliver the expected CHF 90 million of annualized savings and recurring profit improvement by year 4.
- Strategic Investments AcceleratingThe company plans to accelerate strategic investments by a low double-digit CHF million amount in the second half. Investment areas include R&D for next-generation products and technology, manufacturing and supply-chain capabilities, digital systems supporting commercial, retail and finance organizations, and digitalizing and improving the consumer journey.
- Full-Year Guidance RaisedSonova raised its full-year consolidated sales growth guidance to 6% to 8% from 5% to 8% previously. Core EBIT growth guidance increased to 10% to 13% from 7% to 10% previously, while the global hearing aid market growth assumption was raised to 3% to 5% from 2% to 4% previously.
- Employee Engagement ImprovedThe August employee survey showed employee engagement at 74%, up 6 percentage points from the December 2025 baseline. More than 90% of employees understood the behaviors needed to execute the refined strategy.
- Innovation Pipeline Supports Cochlear Implant StrategyIntegro, Roger On Sphere and Phonak connectivity were presented as strategic technology proof points. Integro brings sound localization, smart speech technology and Phonak connectivity to Advanced Bionics, while Roger On Sphere extends real-time AI processing to the microphone and around 90% of the Phonak installed base.
- Disciplined Capital Allocation and M&A PipelineSonova had invested approximately CHF 50 million in retail bolt-on acquisitions by October and remained on track to invest around CHF 80 million to CHF 100 million annually. Management said every deal must meet hurdles for strategic fit, valuation and returns, while maintaining a net debt-to-EBITDA corridor of 1x to 1.5x.
CH:SOON Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| May 18, 2027 | 2027 (Q4) | 6.50- | 5.67 | ― | ― |
| Nov 12, 2026 | 2027 (Q2) | 4.445.18 | 3.56 | 45.51% (+1.62) | |
| May 18, 2026 | 2026 (Q4) | 5.715.67 | 7.07 | -19.80% (-1.40) | |
| Nov 14, 2025 | 2026 (Q2) | 3.933.56 | 3.74 | -4.81% (-0.18) | |
| May 09, 2025 | 2025 (Q4) | 5.897.07 | 5.84 | 21.06% (+1.23) | |
| Nov 19, 2024 | 2025 (Q2) | 3.773.74 | 4.34 | -13.82% (-0.60) | |
| May 14, 2024 | 2024 (Q4) | 5.265.84 | 5.83 | 0.17% (+0.01) | |
| Nov 21, 2023 | 2024 (Q2) | 4.164.34 | 4.9 | -11.43% (-0.56) | |
| May 16, 2023 | 2023 (Q4) | 5.855.83 | 5.49 | 6.19% (+0.34) | |
| Nov 14, 2022 | 2023 (Q2) | 3.994.90 | 4.86 | 0.82% (+0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
